Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.United Therapeutics, a biotechnology company, has appointed Richard Giltner to its board of directors as an independent director.
Subscribe to our email newsletter
According to United Therapeutics, the appointment of Mr Giltner brings the total number of directors to nine, six of whom are independent and not affiliated with the company. Mr Giltner fills a newly-created seat on the board of directors.
Mr Giltner has previously served as a managing director of Societe Generale Asset Management and head of the European office for its fund of hedge funds group, a position he has held since 2006.
From 2003 to 2006, Mr Giltner was the global head of foreign exchange options for the investment banking arm of Societe Generale. Mr Giltner has earned a bachelor of arts degree in economics from Northwestern University in 1987.
Martine Rothblatt, chairman and CEO of United Therapeutics, said: “It feels good to have a new director with extensive experience so closely aligned with the business activities of the great majority of our shareholders. I feel confident that Mr Giltner will help ensure we remain highly responsive to the interests of our shareholders.”